QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis 期刊论文 BIOCHEMICAL PHARMACOLOGY, 2018, 卷号: 150, 页码: 131-140 作者:  Fang, Xiaona;  Xie, Hua;  Luo, Min;  Chen, Zhen;  Wang, Fang 收藏  |  浏览/下载：34/0  |  提交时间：2019/01/08 Angiogenesis  And-tumor activity  Multi-tyrosine kinases inhibitor  PBA2  VEGFR2   SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models 期刊论文 ACTA PHARMACOLOGICA SINICA, 2018, 卷号: 39, 期号: 2, 页码: 243-250 作者:  Jiang, Xi-fei;  Dai, Yang;  Peng, Xia;  Shen, Yan-yan;  Su, Yi 收藏  |  浏览/下载：53/0  |  提交时间：2019/01/08 human cancer  anticancer drug  SOMCL-085  receptor tyrosine kinase  FGFR  xenograft nude mouse model   somcl085anovelmultitargetedfgfrinhibitordisplayspotentanticanceractivityinfgfraddictedhumancancermodels 期刊论文 actapharmacologicasinica, 2018, 卷号: 39, 期号: 2, 页码: 243 作者:  Jiang Xifei;  Dai Yang;  Peng Xia;  Shen Yanyan;  Su Yi 收藏  |  浏览/下载：3/0  |  提交时间：2020/07/01 human cancer  anticancer drug  SOMCL-085  receptor tyrosine kinase  FGFR  xenograft nude mouse model   Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer 期刊论文 ACTA PHARMACOLOGICA SINICA, 2017, 卷号: 38, 期号: 11, 页码: 1533-1542 作者:  Xie, Qin;  Chen, Hui;  Ai, Jing;  Gao, Ying-lei;  Geng, Mei-yu 收藏  |  浏览/下载：17/0  |  提交时间：2019/01/08 thyroid cancer  AL3810  multi-tyrosine kinases inhibitor  angiogenesis  RET   Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors 期刊论文 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 126, 页码: 122-132 作者:  Liu, Yang;  Peng, Xia;  Guan, Xiaocong;  Lu, Dong;  Xi, Yong 收藏  |  浏览/下载：42/0  |  提交时间：2019/01/08 FGFR  KDR  Inhibitor  Anticancer  Ponatinib   evaluationofinvitroandinvivoactivityofamultityrosinekinaseinhibitoral3810againsthumanthyroidcancer 期刊论文 actapharmacologicasinica, 2017, 卷号: 38, 期号: 11, 页码: 1533 作者:  Xie Qin;  Chen Hui;  Al Jing;  Gao Yinglei;  Geng Meiyu 收藏  |  浏览/下载：9/0  |  提交时间：2020/07/01 TARGETED THERAPIES  RET  CARCINOMA  MODELS  GROWTH  TUMORS  CELLS  thyroid cancer  AL3810  multi-tyrosine kinases inhibitor  angiogenesis  RET   DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro 期刊论文 ACTA PHARMACOLOGICA SINICA, 2015, 卷号: 36, 期号: 10, 页码: 1266-1276 作者:  Guo, Xiao-bin;  Zhu, Wei;  Chen, Xian-jie;  Tong, Lin-jiang;  Peng, Xia 收藏  |  浏览/下载：38/0  |  提交时间：2019/01/08 DCLAK11  substituted pyridin-3-amine derivatives  tyrosine kinase  EGFR  HER2  VEGFR2  anticancer  anti-angiogenesis   AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR 期刊论文 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2012, 卷号: 16, 期号: 10, 页码: 2321-2330 作者:  Zhou, Yuanfeng;  Chen, Yi;  Tong, Linjiang;  Xie, Hua;  Wen, Weiwei 收藏  |  浏览/下载：17/0  |  提交时间：2019/01/08 multi-tyrosine kinases inhibitor  angiogenesis  anti-tumour activity   The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo 期刊论文 PLOS ONE, 2008, 卷号: 3, 期号: 11 作者:  Ma, Jingui;  Xin, Xianliang;  Meng, Linghua;  Tong, Linjiang;  Lin, Liping 收藏  |  浏览/下载：14/0  |  提交时间：2019/01/08